-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 22, the official website of NMPA showed that Simcere's bortezomib for injection passed the consistency evaluation of generic drugs
Bortezomib is a proteasome inhibitor.
According to data from Menet.
Sales of terminal bortezomib in public medical institutions in China (unit: ten thousand yuan)
Source: Mi Nei.
With the review of Bortezomib for injection by Simcere Pharmaceuticals, there are currently 8 companies that have reviewed the product, including Chia Tai Tianqing, Yangtze River Pharmaceuticals, CSPC, Qilu Pharmaceuticals, and Hausen Pharmaceuticals
Up to now, Simcere Pharmaceuticals has passed/deemedly passed the consistency evaluation of 16 varieties, including 5 anti-tumor drugs, including nedaplatin for injection, lenvatinib mesylate capsules, and pemetrexed for injection Disodium plug, bendamustine hydrochloride for injection and bortezomib for injection
Data source: Mi Neiwang database, NMPA